Luckin Coffee Inc. (LKNCY.US) said on Tuesday its revenue rose 41.2% year-on-year to 8.87 billion yuan ($1.22 billion) in the first quarter of 2025, as it returned to profitability and same-store sales growth after a year of contraction in 2024.

The coffee store operator said it opened a net 1,757 new stores during the first quarter, raising its total by 7.9% from the end of 2024 to 24,097 at the end of March this year. Of that total, 15,598 stores were self-operated, while the remaining 8,499 were franchised. Revenue from its self-operated stores rose 41.5% year-on-year to 6.48 billion yuan, accounting for about three-quarters of its total.

Same-store sales for the company’s self-operated stores rose 8.1% during the quarter, returning to growth after four consecutive quarters of contraction, including a 20.3% drop in the first quarter of 2024. As its situation improved, the company returned to the black with a profit of 525 million yuan during the quarter, reversing a net loss of 83.2 million yuan a year earlier.

Luckin shares fell 2.6% on Tuesday. The stock is up nearly 40% this year.

By Doug Young

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…